Arrowhead Data Reveal Important Considerations for Future Hepatitis B Treatment
- Results May Guide New Clinical Approaches, Science Translational Medicine Study Shows -
In many patients, integrated HBV DNA appeared to be the dominant source of HBsAg production. The findings expand the understanding of HBV biology and host interactions, and could have important implications for future trial design and endpoint expectations for new therapies developed to cure chronic HBV. These data from study, "RNAi-based treatment of chronically infected patients and chimpanzees implicates integrated hepatitis B virus DNA as a source of HBsAg" were published in Science Translational Medicine.
The paper entitled, "RNAi-based treatment of chronically infected
patients and chimpanzees implicates integrated hepatitis B virus DNA as
a source of HBsAg," by
In the publication, several independent lines of evidence demonstrate that HBsAg is expressed not only from the episomal covalently closed circular DNA (cccDNA) minichromosome, but also from transcripts arising from HBV DNA integrated into the host genome. The latter was a large source of HBsAg production in HBeAg negative chimpanzees and presumed, by extension, in HBeAg negative and NUC experienced patients.
"This is an important finding with wide-reaching implications for the
field because production of viral proteins was previously thought to
depend only on transcription of viral cccDNA. We now understand that
integrated HBV DNA is a means of producing circulating HBsAg that is not
dependent on viral replication, which may contribute to sustained
suppression of the immune system and allow for continued virion
production," commented
About
For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/alerts.cfm.
Safe Harbor Statement under the Private Securities Litigation Reform Act:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the future success of our scientific studies, our ability to successfully develop drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.
Source:
View source version on businesswire.com: http://www.businesswire.com/news/home/20170927006019/en/
626-304-3400
ir@arrowheadpharma.com
or
Investors
and Media:
212-915-2578
britchie@lifesciadvisors.com
www.lifesciadvisors.com
Source:
News Provided by Acquire Media